November 25, 2022 2:13pm

you understand the CEO's vision and how many different “fallbacks” it has; so, if one goes wrong, it's not the end of the world?

Pre-open Indications: 1 Hit and 2 Miss

It’s an honor to be considered the “canary in the (sector) coal mine”! It’s more than opinion, the facts and truth need to be recognized!

Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write

Your portfolio should be profiting from RMi’s analysis -SUBSCRIBE!

Week’s end and in review

 


If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +152.97 points (+0.45%), the S&P close DOWN -1.14 points (-0.03%) while the Nasdaq closed DOWN -58.96 points (-0.52%)

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed the week – mixed post a market holiday.

All three indexes ended the week higher; the Dow is up 1.78%, the S&P 500 is up 1.53% while the Nasdaq lagged but was still up 0.72%.

“Stocks were muted at the start of the week as traders waited for minutes from the Federal Reserve’s November meeting. The minutes showed that the central bank anticipates slowing the pace of interest rate hikes going forward, which gave stocks a boost into the end of the week even amid choppy sessions due to low trading volumes.” <CNBC>

 

Wednesday’s … RegMed Investor’s (RMi) Pre-Open: “shortened trading session ends week. Closing trading at 1 p.m.; month’s end – Wednesday of next week” …  https://www.regmedinvestors.com/articles/12715

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened

  • Friday’s advance/decline line opened negative at 6 up/ 25 down and 4 flats, stayed negative with 13 up/ 20 down and 2 flats at the mid-day, ending with a negative close of 14/21 and 0 flat.
  • Thursday was market holiday
  • Wednesday’s advance/decline line opened positive at 25 up/ 7 down and 3 flats, stayed positive with 22 up/ 12 down and 1 flat at the mid-day, ending with a positive close of 22/12 and 1 flat.
  • Tuesday’s advance/decline line opened negative at 11 up/ 20 down and 4 flats, flipped positive with 17 up/ 16 down and 2 flats at the mid-day, ending with a positive close of 26/7 and 2 flats.
  • Monday’s advance/decline line opened negative at 11 up/ 23 down and 1 flat, stayed negative with 5 up/ 30 down and 0 flat at the mid-day, ending with a negative close of 4/31 and 0 flat.

 

Pre-open indication results: 1 Hit <Sell into Strength:  uniQure NV (QURE +$0.54)> and 2 Miss <CRISPR Therapeutics (CRSP -$0.04), Alnylam Pharmaceuticals (ALNY +$4.23>

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was up +0.20% and the XBI was up +0.07%
  • Thursday was market holiday
  • Wednesday, the IBB was down -0.37% and the XBI was up +0.04%
  • Tuesday, the IBB was up +0.79% and the XBI was up +1.38%
  • Monday, the IBB was down -0.55% and the XBI was down -1.36%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +0.08 points or +0.39% at 20.50
  • Thursday was market holiday
  • Wednesday was down -0.94 points or -4.42% at 20.35
  • Tuesday was down -1.07 points or -4.79% at 21.29
  • Monday was down -0.77. points or -3.33% at 22.35

 

Closing Down (10 or 21):

  • Chinook Therapeutics (KDNY -$1.50),
  • Beam Therapeutics (BEAM -$1.42),
  • BioLife Solutions (BLFS -$0.34),
  • Editas Medicine (EDIT -$0.34),
  • Verve Therapeutics (VERV -$0.30),
  • Intellia Therapeutics (NTLA -$0.21),
  • Agenus (AGEN) -$0.19),
  • Cellectis SA (CLLS -$0.15),
  • Voyager Therapeutics (VYGR -$0.15),
  • Precigen (PGEN -$0.10),

Closing Up (14 of 14):

  • Alnylam Pharmaceuticals (ALNY +$4.23),
  • Ultragenyx (RARE +$1.13),
  • Prime Therapeutics (PRME +$1.02),
  • uniQure NV (QURE +$0.54),
  • Sage Therapeutics (SAGE +$0.34),
  • Ionis Pharmaceuticals (IONS +$0.31),
  • Biostage (BSTG +$0.25),
  • AxoGen (AXGN +$0.25),
  • Fate Therapeutics (FATE +$0.18),
  • bluebird bio (BLUE +$0.07),
  • Regenxbio (RGNX +$0.05),
  • Avrobio (AVRO +$0.03),
  • Vericel (VCEL +$0.03),
  • Sangamo Therapeutics (SGMO +$0.01)

 

Q4 – November

  • Friday closed negative with 14 incliner, 21 decliners and 0 flat
  • Thursday was market holiday
  • Wednesday closed positive with 22 incliner, 12 decliners and 1 flat
  • Tuesday closed positive with 26 incliner, 7 decliners and 2 flats
  • Monday closed negative with 4 incliner, 31 decliners and 0 flats

 

The BOTTOM LINE: I try to keep it simple … and short!

There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions?

In compiling my indication signals, I draw on logic, historical precedents, specific knowledge of the sector and its practices as to lessons learned.  It’s important for investors to identify and determine which indication is actually performance based.

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.